Keizo Koya Email & Phone Number

Keizo Koya is a CEO and President, Founder at SOLA Biosciences Inc based in Greater Boston, United States, North America. With over 30 years of global pharmaceutical R&D and business strategy experience, I am the CEO and President, Founder of SOLA Biosciences, a biopharmaceutical company dedicated to developing gene-therapies for patients with neurodegenerative diseases, and STRATEGIA Holdings, a biopharmaceutical company focused on clinical development of innovative oncology drugs. I have a PhD in organic chemistry and a passion for innovation and collaboration. I founded SOLA Biosciences in 2016 to offer a breakthrough JUMP70 platform technology that harnesses the power of a patient’s own chaperones to repair specific disease-causing misfolding proteins. Our lead programs target conformational diseases such as ALS, HD, and AD. I also founded Strategia Holdings in 2012 to implement a visionary new model for collaborative drug development, generating ten pharmaceutical projects and filing eight INDs in five years. Prior to that, I led R&D for numerous investigational cancer and autoimmune drugs at Synta Pharmaceuticals, Shionogi BioResearch, Fuji ImmunoPharmaceuticals, and Dana Farber Cancer Institute. I have 45 issued and pending U.S. patents and multiple publications in peer-reviewed journals. My mission is to transform the science, technology, and process of developing new, effective, and affordable therapeutics for patients whose needs are unmet.